Recent advances in molecular and genetic profiling have improved our understanding of GBM’s complex biology, highlighting the role of mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1/2), MGMT promoter methylation, and other markers that are central to GBM’s pathogenesis and resistance mechanisms [3]. This evidence concerns the gene IDH1 and glioblastoma.